PsO/PsA patients have an ⬆️ CV risk brought about by traditional and CV risk factors. Do you perform regular CV risk screening in your patients? @RheumNow #APLAR25 https://t.co/BGNKrKeLsI

IL-17is demonstrate efficacy in SpA tx Comparable with TNFis & JAKis in terms of achieving ASAS40 response rates IL-17is are generally well-tolerated w/⬇️TB risk (very important tx consideration esp in Asia) But watch out for candidal infx, IBD exacerbation @RheumNow #APLAR25 https://t.co/rSUJlZOhKV

Evidence of immune ageing detected at the earliest stages of RA. Study of 69 controls, 32 CSA, 44 undiff. arthritis (UA), 23 early RA, & 56 DMARD naive RA. UA & CSA had reduced naive CD4 T cells. Th17, Tregs &7 senescent T cells, were only seen once RA was established. https://t.co/c1wiA5gvM5

Target trial emulation looked at CV (MACE) events in 18,120 propensity score–matched adults with gout starting allopurinol who were given NSAIDs or colchicine for prophylaxis. MACE & CV death were signif. higher w/ NSAIDs vs Colchicine (HRs of 1.56 and 2.50), respectively. https://t.co/0T8slmPBng

Hospital for Special Surgery (HSS) reports that ear acupuncture applied during hip replacement surgery reduces pain and lessens opioid use over the weeks to follow. https://t.co/lOrwb1DzW5 https://t.co/6rkHNTwaAl

RCT of 800 adults w/ Chronic LBP, acupuncture (AP) was compared usual care or AP +/- added maintenance found that acupuncture improved pain-related disability at 6 months and 12 months, with no statistically discernible benefit of additional maintenance sessions. https://t.co/suy09fGxxI

SLE and Osteoporosis Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease that can present with a variety of signs and symptoms and organ involvement. Comorbidities further complicate the disease course that may lead to poor health-related quality of life and https://t.co/8ZmtLjzbqA

SMART study - Single vs. Split Dose Methotrexate in RA Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients. https://t.co/JN5wPGNjao https://t.co/lizsrtVHwf

Future Perspectives of Rheumatoid Arthritis Dr. Kuni Yamaoka, shares highlights from the Future Perspectives of Rheumatoid Arthritis session at the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/LGLqe48R2L https://t.co/Kwp3cFPtyw

QD Clinic: Progressive RA-ILD Management Dr. Richard Conway, a rheumatologist in Dublin, discusses a case about managing progressive rheumatoid arthritis-interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September https://t.co/dLCXeXwl7w

What are the Pros and Cons of autologous CAR T cell therapy? Summary slide from Georg Schett who also mentioned the exciting in vivo CAR approach using nanoparticules in myeloma, something to stay tuned for @RheumNow #APLAR25 https://t.co/kWjrx6N9Dv

In lupus patients presenting with demyelinating symptoms, consider a probable disease overlap between NPSLE and NMOSD. >>>> serum AQP4 is highly specific for NMOSD. @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/2Z8rbJ3a1c